The Catalyst

Most Recent Posts


This week, The Catalyst focused on the challenges facing our nation's health care system.

12.20.12 | By Mark Grayson

12.20.12 | By Stephanie Fischer

A new Food and Drug Administration (FDA) infographic may help patients and their families better understand the lengthy drug development and review process, which is somewhat complicated and has many steps to ensure safety and eff


Today, we've got a guest blog post from an important voice in the fight against chronic disease - Kenneth E. Thorpe, PhD, the Healthy Policy Chair at Emory University and Chairman of the Partnership to Fight Chronic Disease (PFCD).

12.17.12 | By Rick Smith

Back when I was a kid it was common, sadly, for people in their middle ages to suffer from fatal heart attacks or debilitating strokes.


A guest post today on by Merck Chairman, President and CEO Ken Frazier puts the fiscal cliff and medical innovation in an i


People the world over are living longer. We've talked about it before, now its getting recognition in the main stream media...

12.13.12 | By Jay Taylor, By Jay Taylor

A compelling new report by the Global Intellectual Property Center (GIPC), highlights the strengths and weaknesses of 11 economically and geographically diverse countries.


As the clock ticks closer to the end of the year, the fiscal cliff negotiations are anticipated to run through the holidays.


Whether it is a team approach in the office or working in tandem with friends or family members, many of us have felt the power of collaboration in delivering better outcomes. When it comes to our health, collaboration is also an essential ingredient to improving our health and our medicines.


The open enrollment period for Medicare Part D and Medicare Advantage has now passed, but there are exceptions that may be of interest to family and friends. For example, CMS is providing a grace period for eligible seniors and disabled Americans who have been affected by Hurricane Sandy.


In light of the report we just released highlighting the medicines in development for HIV/AIDS, I thought this interview with a top infectious disease researcher was worth re-posting.


This week we featured a number of posts on Medicare Part D, research and development and innovation.


Below is the latest guest post in our "Part D Perspectives" series, which we'll be hosting throughout the year to share thoughts on the program and its importance.